AlcoMedix is a startup focused on the synthesis of heterocyclic alcohol-based esters derived from non-steroidal anti-inflammatory drugs (NSAIDs), aiming to reduce their gastrointestinal and renal side effects. By chemically modifying existing NSAIDs through esterification with bioactive heterocyclic alcohols, the company seeks to enhance therapeutic efficacy while improving patient safety. This innovative approach bridges pharmaceutical chemistry and drug safety to develop next-generation anti-inflammatory solutions.